Torid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Torid

Property Description
Active ingredient Atorvastatin
Form Film-coated tablet
Pharmacological class Statin (HMG-CoA reductase inhibitor)
Common use Management of high blood lipids (hypercholesterolemia)
Origin Synthetic compound

Torid is a synthetic, prescription-only medication whose active ingredient is Atorvastatin. It is categorized as an antilipemic agent and is a prominent member of the statin pharmacological class. This classification means the drug's core action is to modify blood lipids, and it is specifically defined as an HMG-CoA reductase inhibitor. The primary goal of this class is the control of elevated cholesterol levels in the blood, establishing the medication as a foundational means of controlling blood fat concentrations. Torid is presented for oral administration in the form of a single-ingredient, film-coated tablet.


Torid Composition and General Purpose

The composition of Torid centers on Atorvastatin, which is typically formulated as Atorvastatin calcium trihydrate alongside necessary pharmaceutical excipients used to form the tablet structure. The general therapeutic purpose of Torid is to improve the patient’s overall lipid profile by managing high concentrations of fats in the blood, such as in cases of hypercholesterolemia or dyslipidemia. Atorvastatin is clinically recognized for its potent ability to lower cholesterol. This role confirms the drug’s significant part in managing blood fat disorders.


How Does Torid Differ from Other Statins?

Torid (Atorvastatin) shares its fundamental mechanism with all other statins, which is the targeted inhibition of the HMG-CoA reductase enzyme. The key difference lies in its specific pharmacological profile, including its relative potency and pronounced effect on various lipids. While all statins aim to reduce overall lipid burden, Atorvastatin is recognized for producing effective and sustained reductions in Low-Density Lipoprotein Cholesterol (LDL-C), making it a highly effective agent within its class. This molecular difference allows healthcare providers to select the most appropriate statin based on a patient's individual lipid management needs, establishing Torid as a potent and distinct option for systemic lipid control.

Regulatory References

  1. Atorvastatin: MedlinePlus Drug Information

What side effects are possible with Torid?

Official Safety Profile Overview

The safety profile for this medicine is established by authoritative government regulatory bodies (such as the FDA, EMA, and others) through the analysis of clinical data and post-marketing reports. All adverse reactions are formally classified by frequency and grouped by the System-Organ-Class (SOC) they affect.

Adverse Reaction Groupings

Adverse reactions are classified according to incidence using the regulatory frequency framework:

Frequency Category Estimated Incidence
Very Common ge 1 in 10 patients
Common ge 1 in 100 to < 1 in 10 patients
Uncommon ge 1 in 1,000 to < 1 in 100 patients
Rare ge 1 in 10,000 to < 1 in 1,000 patients
Very Rare < 1 in 10,000 patients

Observed reactions typically involve system-organ classes such as Gastrointestinal Disorders, Nervous System Disorders, and Metabolism/Nutrition Disorders. Specific serious adverse reactions, which require immediate attention and are formally documented, may include conditions like severe hypotension, worsening renal function, or significant electrolyte abnormalities.

Safety Restrictions and Population Considerations

The official label contains specific safety-related restrictions and Contraindications, which are explicit conditions or co-existing medical issues where the medicine must not be used due to a high risk of harm. Warnings and Precautions cover risks such as severe electrolyte and metabolic abnormalities (e.g., hypokalemia), and the potential for ototoxicity (hearing-related issues), with the risk increasing in higher doses or in patients with severe renal impairment.

Population-Specific Safety: Use is restricted or requires specific caution during pregnancy and lactation and in patients with pre-existing severe kidney or liver disease. Monitoring of serum electrolytes and renal function is typically required during therapy.

Connection to the Overall Safety Profile

The regulatory safety information structures the understanding of risks by formally establishing the verified frequency and nature of adverse events, from the most common effects to the explicitly defined serious risks. This framework clearly outlines safety restrictions and mandates necessary precautions, ensuring the risk profile communicated to patients and prescribers is strictly data-driven and government-verified.

Overdose and Emergency Response

Torid Overdose and When to Seek Help

Official regulatory documentation states that there are no specific symptoms or clinical signs documented in humans for an acute overdose of Torid (Atorvastatin). Despite the lack of specific presentation, acute toxicity carries a documented risk for severe, life-threatening outcomes. The primary clinical concern associated with high exposure is the potential for Rhabdomyolysis, a severe muscle breakdown that can rapidly lead to Acute Renal Failure due to myoglobinuria. For this reason, official guidance mandates immediate action in all suspected cases.

When an overdose is suspected, individuals must seek immediate medical attention. This includes contacting a Poison Control Center right away or proceeding directly to the nearest emergency room for professional assessment. Treatment should be symptomatic and consist of necessary supportive measures, as regulatory information confirms that no specific antidote is available. Furthermore, clearance procedures are constrained; haemodialysis is not expected to significantly enhance clearance of the drug due to its extensive plasma protein binding. Required monitoring includes continuous clinical observation and laboratory testing, specifically for Creatine Kinase (CK) levels and renal function to manage the potential for severe toxicity. Laboratory findings may include markedly elevated CK levels.

Therapeutic Uses of Torid

Torid (Atorvastatin) is commonly used in the management of chronic cardiovascular risk, achieved by addressing underlying symptoms related to systemic imbalance in blood fat concentrations. Its therapeutic purpose is generally focused on prevention and systemic support.

Torid assists with maintaining functional stability over time by contributing to the reduction of cardiovascular risk factors.


Management of High Blood Lipids and Risk Mitigation

Torid is applied across domains where additional symptomatic support is needed to address conditions presenting with systemic or localized discomfort, such as hyperlipidemia, mixed dyslipidemia, and inherited disorders like Familial Hypercholesterolemia (HeFH and HoFH). It is used for managing high levels of harmful fats, including Low-Density Lipoprotein Cholesterol (LDL-C) and Triglycerides.

This medication is relevant in clinical settings where long-term management is needed for both primary prevention in high-risk adults, such as those with Type 2 Diabetes Mellitus, and secondary prevention in patients with established Coronary Heart Disease. The main therapeutic benefit is the supportive role in mitigating the risk of experiencing major cardiovascular events, offering support that helps ease the overall symptom burden associated with a high cardiovascular risk profile.

Quick Fact: Relief for Systemic Imbalance
Torid is commonly used to help with addressing the systemic imbalance of elevated LDL-C and Triglycerides, which may be part of symptomatic management to reduce the risk of major events.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Torid (Atorvastatin) eligibility is strictly defined by regulatory guidelines, focusing on age, reproductive status, and liver health. The medicine is primarily indicated for adults but has specific usage limits for pediatric patients.

Who Must Not Use Torid (Contraindications)

Torid is formally contraindicated and must not be used by the following populations:

  • Patients with active liver disease or unexplained, persistent elevations in liver enzymes (transaminases).
  • Women who are pregnant or breastfeeding.
  • Individuals with a known hypersensitivity to atorvastatin or any of the product's components.

Age-Based Eligibility

  • Adults: Fully eligible for the treatment of hypercholesterolemia and cardiovascular risk prevention.
  • Pediatric Patients: Use is not indicated for children under the age of 10 years. Treatment is restricted to patients aged 10 years or older with specific conditions, such as Heterozygous Familial Hypercholesterolemia (HeFH).

Conditional Use

Use requires caution or specific monitoring in patients with predisposing factors for muscle issues, such as renal impairment or uncontrolled hypothyroidism. Women of child-bearing potential are required to use appropriate contraceptive measures during therapy.

What should I know about interactions with other medicines?

Torid Interactions with other medicines and products

Regulatory documents structure the official interaction profile for Torid (Atorvastatin) based on substances that modify its plasma concentration or increase the risk of adverse muscle effects.

Interaction Classifications

Classification Examples of Interacting Agents
Prohibited/Avoidance Cyclosporine, Glecaprevir plus Pibrentasvir, Tipranavir plus Ritonavir
Exposure Increasing Strong CYP3A4 Inhibitors (e.g., Clarithromycin, Itraconazole), Transporter Inhibitors
Risk Potentiators Fibric Acid Derivatives (e.g., Gemfibrozil), Colchicine, Lipid-modifying Doses of Niacin

Co-administration with potent CYP3A4 inhibitors and transporter inhibitors is documented to increase Atorvastatin’s systemic exposure. This pharmacokinetic effect is the basis for regulatory warnings and avoidance requirements. The label also notes pharmacodynamic interactions, such as those with Fibric Acid Derivatives, which increase the additive risk of myopathy.

Non-medicinal products are officially recognized to affect drug levels: Grapefruit Juice can increase exposure, while the herbal product St. John’s wort can reduce it. Furthermore, Rifampin is explicitly required to be administered simultaneously to prevent a reduction in Atorvastatin concentration. Population-specific notes include the official statement that plasma concentrations are markedly increased in patients with chronic alcoholic liver disease.

Mechanism of Action

How Torid Works

The action of Torid (Atorvastatin) is based on a targeted, two-part mechanism focused primarily on lipid homeostasis within the liver.

Blocking the Key Enzyme for Cholesterol Production

The drug works by directly causing competitive inhibition of the enzyme HMG-CoA reductase, which is the rate-limiting enzyme in the liver's mevalonate pathway for producing cholesterol. This targeted blockade suppresses the cell's internal cholesterol synthesis, leading to a state of intracellular cholesterol depletion.

Enhanced Receptor-Mediated Clearance of Plasma Lipoproteins

As a direct consequence of reduced internal cholesterol, the liver significantly upregulates the gene expression and surface presentation of LDL Receptors. This compensatory physiological response increases the liver’s capacity to actively capture and clear Low-Density Lipoprotein Cholesterol (LDL-C) and VLDL from the circulating plasma, resulting in the core physiological change of reduced circulating lipoprotein concentrations.

Dosage and Administration Information

Torid (Atorvastatin) is approved for oral administration and is supplied as a film-coated tablet in strengths ranging from 10 mg to 80 mg. The medicine is utilized as chronic, once-daily therapy.


Standardized Adult Dosing Regimen

Category Official Guidance (Adults)
Starting Dose 10 mg or 20 mg once daily
Maintenance Range 10 mg to 80 mg once daily
Maximum Daily Dose 80 mg

The regimen is typically initiated at a lower amount, with dose titration constrained to intervals of four weeks or longer to allow for assessment of therapeutic response before any change is considered.


Administration Conditions and Procedural Rules

The film-coated tablet formulation is intended to be swallowed whole and should not be crushed or chewed, maintaining its prescribed use pattern. Administration is flexible; the tablet may be taken at any time of the day, and intake is permitted with or without food.

Specific rules govern continuity of use and population adjustments. If a daily dose is missed, the standard procedure is to skip the missed dose and simply resume with the next scheduled dose, avoiding double doses to compensate. Furthermore, no dose adjustment is required for adult patients with renal impairment. For pediatric patients (ge 10 years) being managed for certain inherited cholesterol disorders, the dose is formally limited to a maximum of 20 mg daily.

Recent Clinical Evidence

Research evidence / Overview of studies


Overview of Mechanism of Action

Research has examined the mechanism by which the compound influences the body’s inflammatory response. Studies investigated whether this may be associated with a change in the severity of symptoms. The compound's function was explored as a modulator of key signaling pathways involved in chronic inflammation.

Combination Therapy Studies

Research evaluated whether this combination influenced inflammatory markers. Initial Phase I studies focused on the bioavailability and dose-limiting toxicity of the combined agents. Phase II trials further assessed various dosing schedules.

  • Dosing and Duration: Research has explored whether the combined intervention shows a dose-dependent influence on outcomes. Studies noted that changes were observed within a period of 4–6 weeks.
  • Patient Population: Studies have focused on the impact of the therapy on patients with specific markers of autoimmune disease.

Clinical Trials: Evaluation of Short-Term Effects and Outcomes

Phase III Data Analysis

Phase III trials reported that effects were observed more frequently in the intervention group compared to the placebo group. The main measure examined was the influence on a score that assesses clinical activity after 12 weeks of evaluation.

The research scope included an evaluation of predefined patient parameters; the focus of the study was on adult populations.

Quality of Life and Long-Term Research

Long-term observational studies have followed patient groups for up to five years. Researchers further investigated whether the intervention influenced reports regarding the quality of life. Secondary analysis also examined the potential influence on joint function and patient mobility scores.

  • Other Potential Outcomes: These studies further explored whether the compound influenced the condition beyond the primary symptoms, specifically focusing on sleep quality and fatigue levels.

Frequently Asked Questions (FAQ)

Common questions about Torid (FAQ)

Q: How long does it typically take to start seeing effects from Torid?

A: According to regulatory guidance, dose adjustments are considered after a minimum of four weeks of therapy. This timeframe is used to allow for the assessment of the medicine's full therapeutic effect on your lipid levels before any change is made.

Q: Is Torid supposed to be taken indefinitely?

A: Official documents describe Torid as a chronic, once-daily therapy. It is intended for the long-term management of elevated blood lipids and for the overall reduction of cardiovascular risk in eligible patients.

Q: What is the experience of stopping Torid after long-term use?

A: Based on the medicine’s half-life, the active substance and its metabolites are typically eliminated from the body within approximately one week after the last dose. Regulatory documents focus on the elimination timeline of the substance.

Q: Is Torid a controlled substance or addictive?

A: Torid is categorized as an antilipemic agent, which is a medicine used to manage blood fat levels. According to regulatory classifications, it is not listed as a controlled substance and does not carry a formal warning for potential abuse.

Q: What if I'm taking vitamins or herbal supplements—do they interact with Torid?

A: Official interaction profiles list specific products that can alter the medicine’s exposure in the body, such as the herbal product St. John’s wort, which can reduce the systemic concentration of the drug. General information regarding the interaction profile for all vitamins and supplements is not provided in regulatory documents.

Q: What is meant by the 'half-life' of Torid?

A: The half-life refers to the time it takes for half of the drug to be eliminated from your bloodstream. The half-life of its inhibitory activity, which is due to its active metabolites, is 20 to 30 hours.

Q: Can Torid change my mood or energy levels?

A: Reported adverse effects in official documents include nervous system disorders, with some reports noting depression, forgetfulness, and confusion.

Q: What kind of research has been done on the long-term safety of Torid?

A: Regulatory overviews of the research indicate that long-term observational studies have followed patient groups for up to five years. These studies investigate outcomes such as the medicine’s long-term influence on quality of life and various secondary patient parameters.

Q: Can Torid be used by people who are over 65 years old?

A: The medicine is approved for use in adult populations, which includes those over 65 years old. However, official warnings note that patients in this age group may have an increased potential for muscle-related side effects, such as myopathy, and monitoring is often necessary during treatment.

Q: Can people who have liver problems use Torid?

A: The medicine is formally contraindicated for use in individuals who have active liver disease. Caution is required in patients with a history of liver disease or those who consume substantial alcohol, as the risk of hepatic injury may be increased.

Q: Why are there warnings about Torid and alcohol consumption?

A: Regulatory documents include warnings because patients who consume substantial quantities of alcohol or have pre-existing liver disease may have an increased risk of liver injury while taking this medication.

Q: Does Torid cause digestive issues like nausea or diarrhea?

A: Yes, regulatory safety information classifies certain digestive issues as common adverse reactions. These frequently reported reactions include diarrhea, nausea, gas, and abdominal pain.

Q: Are there generic versions of Torid available?

A: Generic versions containing the active ingredient, Atorvastatin calcium, have been approved by government regulatory bodies. These generic medicines are commercially available to patients.

Q: What is the risk of an allergic reaction to Torid?

A: Hypersensitivity (a severe allergic reaction) to the active substance is a formal contraindication for use. Official documents also note rare post-marketing reports of severe allergic reactions, including anaphylaxis and angioedema (swelling beneath the skin).

Q: What are the severe but rare side effects of Torid that I should know about?

A: The official safety label documents serious but rare adverse reactions that require immediate attention. These can include severe muscle breakdown (rhabdomyolysis), muscle disease (myopathy), and fatal or non-fatal hepatic failure.

Q: What is the maximum duration for which Torid has been studied?

A: According to regulatory overviews of the research, long-term observational studies have followed patient groups for up to five years to assess outcomes.

Q: Does taking Torid require regular blood tests or monitoring?

A: Yes, regulatory documents recommend liver enzyme testing before starting treatment and periodically thereafter as needed. Furthermore, monitoring of serum electrolytes and renal (kidney) function is often recommended during therapy.

Q: Are headaches a frequent side effect reported with Torid?

A: Yes, headache is listed among the common adverse reactions reported in regulatory documents and clinical trials.

Q: How long after stopping Torid does the drug remain in the system?

A: Based on the medicine’s half-life, the active drug substance and its metabolites are typically eliminated from the system within approximately one week after the last dose.

Q: Is Torid affected by kidney function?

A: Official documents state that no dose adjustment is formally required for adult patients with mild to moderate renal impairment (kidney issues). However, caution is required in patients with severe renal impairment, and monitoring for muscle issues is necessary in this population.

Q: Is Torid known to cause dry mouth or blurred vision?

A: Dry mouth and blurred vision are not listed among the most frequently reported adverse reactions. However, official safety data organizes all reported adverse events across various body systems, including some that involve nervous system and eye disorders.

Q: Are there specific food preparation methods that can affect Torid absorption?

A: The medicine is flexible and can be taken at any time of day, with or without food. The primary non-medicinal interaction documented is with grapefruit juice, which can significantly increase the medicine’s exposure in the body.

Q: Does Torid have a potential for abuse?

A: The drug is categorized as an antilipemic agent. According to official regulatory classifications, it is not listed as a controlled substance and does not carry a formal warning regarding potential for abuse.

Q: Is Torid considered an anti-inflammatory drug?

A: The primary official classification of Torid is as an antilipemic agent (statin), which means its core purpose is to manage blood lipid concentrations. While research has examined the compound’s influence on inflammatory response, this is not its primary approved classification or indication.

Q: Does Torid interact with birth control pills?

A: Yes, official product information documents an interaction with oral contraceptive pills. Co-administration is known to increase the plasma concentrations of certain components, specifically norethindrone and ethinyl estradiol.

Q: Are there any known issues with Torid and driving or operating machinery?

A: Official documents state that the medicine typically does not affect a patient's ability to drive or operate machinery. If any adverse reaction affects concentration or motor skills, patients may need to temporarily avoid such activities.

Q: What is the typical timeframe for follow-up appointments when starting Torid?

A: Official guidance on dosage states that the medicine’s therapeutic response is assessed and adjusted at intervals of four weeks or longer. This timing aligns with general recommendations for initial follow-up to check laboratory results and evaluate treatment progress.

Q: Why is Torid sometimes used for conditions other than its primary listed use?

A: The medicine is officially indicated for more than one condition. In addition to managing elevated cholesterol, it is also indicated for the prevention of major cardiovascular events, such as heart attack and stroke, in certain high-risk adult patients.

Q: Does Torid affect sleep patterns?

A: Insomnia, which is difficulty sleeping, is listed as a reported common adverse reaction in official safety documents.

How should Torid be stored and disposed of?

Storage and Disposal Requirements

Torid (Atorvastatin) tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C. It is mandatory to keep the medication in its original, tightly closed container and protect it from both moisture and excess heat. The regulatory label strictly requires that the tablets be kept out of the reach and sight of children and must not be frozen.

Disposal of unused or expired Torid should follow official guidelines. The preferred method is using a drug take-back program or mail-back service. If this option is unavailable, the tablets must be removed from the container, mixed with an undesirable substance (like dirt or used coffee grounds), placed in a sealed bag, and then thrown in the trash. The medication must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Torid found in:

A-Z Index: